Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-SSH2 mRNAs is a collective term referring to the entire population of messenger RNA transcripts in a cell that do not encode the Slingshot Homolog 2 (SSH2) protein. This is not a recognized therapeutic target or a single biological entity; rather, it is a classification used in the development of gene-silencing therapeutics, such as siRNAs or antisense oligonucleotides, to define the off-target transcriptome. SSH2 is a protein phosphatase that plays a critical role in actin cytoskeleton dynamics by dephosphorylating and activating cofilin (UniProt Q76I76, PubMed 12134158). In pharmacological research, ensuring that a drug does not interact with non-SSH2 mRNAs is essential for maintaining high specificity and avoiding unintended gene suppression, which could lead to cellular toxicity or adverse systemic effects (PubMed 15561762). Because this category encompasses thousands of diverse transcripts, it does not have a specific biological function or disease role. The term is primarily used to denote the absence of unintended interactions during the validation of gene-specific knockdown or modulation strategies.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-SSH2 messenger RNAs (Non-SSH2 mRNAs).